| (Values in U.S. Thousands) | Jun, 2021 | Mar, 2021 | Dec, 2020 | Sep, 2020 | Jun, 2020 |
| Sales | 0 | 0 | 0 | 0 | 15,000 |
| Sales Growth | unch | unch | unch | -100.00% | unch |
| Net Income | -4,410 | -4,440 | -4,720 | -4,960 | 9,280 |
| Net Income Growth | +0.68% | +5.93% | +4.84% | -153.45% | +336.73% |
Aerpio Pharmaceuticals Inc (ARPO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company' product candidates include AKB'9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States.